Estimating hepatitis C infection acquired in England, 1986-2000

Epidemiology and Infection

Volumn 137, Issue 9, 2009, Pages 1249-1254

  Balogun, M A ^a   Vyse, A J ^a   Hesketh, L M ^b   Kafatos, G ^a   Parry, J V ^a,c   Ramsay, M E ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

England; Hepatitis C virus; Incidence; Prevalence; Residual specimens

Indexed keywords

HEPATITIS C ANTIBODY;

ARTICLE; BIRTH; BLOOD SAMPLING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG USE; FEMALE; GENDER; HEALTH SURVEY; HEPATITIS C; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PREVENTION AND CONTROL; PUBLIC HEALTH; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; GREAT BRITAIN; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; REGRESSION ANALYSIS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 69949185554     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268809002143     Document Type: Article

References (29)

1. Anon. Hepatitis C - global prevalence (update). Weekly Epidemiology Record 1999; 74: 425-427.
2. Majid A, et al. Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities. Journal of Medical Virology 1995; 46: 48-51.
3. Lamden KH, et al. Hepatitis B and hepatitis C virus infections: Risk factors among drug users in North West England. Journal of Infection 1998; 17: 260-269.
4. Hope V, et al. Prevalence of hepatitis C among injection drug users in England and Wales. Is harm reduction working? American Journal of Public Health 2001; 91: 38-42.
5. Hutchinson SJ, et al. Prevalence of hepatitis C among injectors in Scotland 1989-2000; declining trends among young injectors halt in the late 1990s. Epidemiology and Infection 2002; 128 473-477.
6. Soldan K, Barbara JAJ, Heptonstall J. Incidence of seroconversion to positivity for hepatitis C antibody in repeat blood donors in England, 1993-5. British Medical Journal 1998; 316: 1413-1417.
7. Balogun MA, et al. The prevalence and genetic diversity of hepatitis C infection in antenatal clinic attenders in two regions of England. Epidemiology and Infection 2000; 125: 705-712.
8. Ward G, et al. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: Uptake and acceptability of named antenatal testing. Gut 2000; 47: 277-280.
9. Goldberg D, et al. Hepatitis C virus among high and low risk pregnant women in Dundee: Unlinked anonymous testing. British Journal of Obstetrics and Gynaecology 2001; 108: 365-370.
10. Wreghitt TG, et al. Transmission of hepatitis C virus by organ transplantation in the United Kingdom. Journal of Hepatology 1994; 20: 768-772.
11. Zuckerman J, et al. Prevalence of hepatitis C antibodies in clinical health care workers. Lancet 1994; 343: 1618-1620.
12. HPA. Hepatitis C in England: The Health Protection Agency Annual Report 2007. London: Health Protection Agency Centre for Infections, December 2007.
13. Balogun MA, et al. The prevalence of hepatitis C in England and Wales. Journal of Infection 2002; 45: 119-226.
14. Osborne K, et al. Ten years of serological surveillance in England and Wales: Methods, results, implications and action. International Journal of Epidemiology 2000; 29: 362-368.
15. Vyse AJ, et al. Interpreting serological surveys using mixture models: The seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiology and Infection 2006; 134: 1303-1312.
16. Vyse AJ, et al. Seroprevalence of antibody to varicella zoster virus in England and Wales in children and young adults. Epidemiology and Infection 2004; 132: 1129-1134.
17. Nardone A, et al. Seroepidemiology of Bordetella pertussis in England and Wales. Vaccine 2004; 22: 1314-1319.
18. Vyse AJ, et al. The burden of Helicobacter pylori in England and Wales. Epidemiology and Infection 2002; 128: 411-417.
19. Maple PAC, et al. Immunity to diphtheria and tetanus in England and Wales. Vaccine 2001; 19: 167-173.
20. Morris MC, et al. The changing epidemiological pattern of hepatitis A in England and Wales. Epidemiology and Infection 2002; 128: 457-463.
21. Vyse AJ, Hesketh LM, Pebody R. The burden of infection with cytomegalovirus in England and Wales: How many women are infected in pregnancy? Epidemiology and Infection. Published online: 15 September 2008. doi:10.1017/S0950268808001258.
22. Kelly H, et al. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 2002; 20: 3130-3136.
23. Gungabissoon U, Balogun MA, Ramsay ME. Hepatitis C virus: laboratory surveillance in England and Wales, 1992-2004. Epidemiology and Infection 2007; 135: 541-548.
24. Balogun MA, et al. A national survey of genitourinary medicine clinic attenders provides little evidence of sexual transmission of hepatitis C virus infection. Sexually Transmitted Infections 2003; 79: 301-306.
25. Brant LJ, et al. Sentinel laboratory surveillance of hepatitis C antibody testing in England: Understanding the epidemiology of HCV infection. Epidemiology and Infection 2007; 135: 417-426.
26. HPA. Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB and the UASSG. Shooting up: Infections among injecting drug users in the United Kingdom 2005. London: Health Protection Agency, October 2006.
27. Sutton AJ, et al. Modelling the characteristics of the male injecting drug user population in England and Wales. International Journal of Drug Policy 2005; 16: 176-182.
28. Sweeting M, et al. The burden of hepatitis C in England. Journal of Viral Hepatitis 2007; 14: 570-576.
29. Hughes G, Simms I, Leong G. Data from UK genito-urinary medicine clinics, 2006: A mixed picture. Sexually Transmitted Infections 2007; 83: 433-435.